# Luseogliflozin Persistently Lowers Glycemia and Body Weight Over a Period of Two Years in Patients With Type 2 Diabetes

## TL;DR

Luseogliflozin, a diabetes drug, consistently lowers blood sugar and body weight over two years in type 2 diabetes patients.

## Contribution

This study provides long-term evidence of luseogliflozin's sustained efficacy in glycemic and weight control over two years.

## Key findings

- Luseogliflozin significantly reduced plasma glucose levels after one and two years of treatment.
- The drug led to a sustained decrease in HbA1c levels by over 1% after two years.
- Body mass index and blood pressure also showed significant reductions over the study period.

## Abstract

Introduction: Sodium-glucose co-transporter-2 inhibitor (SGLT2i) was introduced as an oral hypoglycemic agent. Thereafter, it was revealed that SGLT2i had multifaced effects, such as renal function and heart failure. Luseogliflozin is one of the SGLT2i. However, the long-term effects of luseogliflozin on glycemic control, body weight, and body mass index have not yet been established.

Aims: This study aimed to determine the long-term effects of luseogliflozin, an SGLT2i, on plasma glucose (PG), body weight (BW), body mass index (BMI), and blood pressure (BP) in patients with type 2 diabetes.

Methods: Luseogliflozin was administered continuously in an outpatient clinic for at least two years to 35 SGLT2i-naive patients. Random plasma glucose (RPG), hemoglobin A1c (HbA1c) level, BW, BMI, and BP were measured every six months.

Results: At baseline, the patients had a median age of 63 years and a median diabetes duration of seven years. The mean RPG levels at the initiation of luseogliflozin and after 1 and 2 years were 213.5, 155.7, and 164.4 mg/dL, respectively. The reductions from baseline at both 1 year (p<0.001) and 2 years (p=0.012) were statistically significant. Compared with the baseline, the mean HbA1c level significantly decreased by 0.98% after 1 year (p<0.001) and by 1.08% after 2 years (p<0.001), respectively. The mean BMI significantly decreased from 27.41 kg/m² at baseline to 26.53 kg/m² after 1 year (p<0.001) and 26.37 kg/m² after 2 years (p<0.001). Systolic/diastolic blood pressure, initially (138.2/79.2 mmHg), was reduced to 132.9/74.5 mmHg after 1 year, with statistically significant declines in both systolic (p=0.035) and diastolic (p=0.016) pressure compared to baseline.

Conclusions: The effects of luseogliflozin on glucose and BW reduction were sustained for at least two years, indicating similarity to other SGLT2 inhibitors.